pancreatic%20cancer
PANCREATIC CANCER
Pancreatic cancer is malignancy arising from the pancreas.
It is the 13th most common cancer in the world, 10th most common in the United States, and 4th leading cause of cancer-related deaths in the United Stated and Europe.
Exocrine tumors account for 95% of malignant pancreatic disease.
It is more common in women.
The median age of occurrence is at 71 years old.

Pancreatic%20cancer Management

Follow Up

  • Assess for suspected recurrence
  • Patients with poor prognostic or high-risk features for disseminated disease include patients with:
    • Large primary tumors
    • Large regional lymph nodes
    • Markedly elevated CA 19-9
    • Extreme pain, excessive weight loss or highly symptomatic
    • Borderline resectable tumors
  • Recommended follow-up schedules:
    • 1st 2 years: History and physical examination, CA 19-9 and CT scan every 3-6 months
    • 3rd year and thereafter: History and physical examination, CA 19-9 and CT scan annually
  • For post-op patients:
    • If with elevated serum CA 19-9 levels, serum CA should be measured every 3 months for 2 years and abdominal CT scan performed every 6 months
    • Insulin therapy may be prescribed after total pancreatectomy

Prevention

  • There are no definite measures to prevent PC but there are measures which can lower the risk for pancreatic cancer
Alcohol Consumption
  • Avoid or limit consumption of alcohol
Diet
  • Increase consumption of vegetables and whole grains
  • Decrease consumption of sugar
Exposure to Chemicals
  • Avoid exposure to certain chemicals
Smoking
  • Most established and most avoidable risk factor for PC
  • Patients should be discouraged from smoking, or for smokers, encouraged to quit smoking
Weight Management
  • Maintain normal body weight
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 25 Nov 2020
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.